Pluripotent Stem Cells as a Potential Tool for Disease Modelling and Cell Therapy in Diabetes

  title={Pluripotent Stem Cells as a Potential Tool for Disease Modelling and Cell Therapy in Diabetes},
  author={Essam M. Abdelalim and Am{\'e}lie Bonnefond and Annelise Bennaceur-Griscelli and Philippe Froguel},
  journal={Stem Cell Reviews and Reports},
  pages={327 - 337}
Diabetes mellitus is the most prevailing disease with progressive incidence worldwide. To date, the pathogenesis of diabetes is far to be understood, and there is no permanent treatment available for diabetes. One of the promising approaches to understand and cure diabetes is to use pluripotent stem cells (PSCs), including embryonic stem cells (ESCs) and induced PCSs (iPSCs). ESCs and iPSCs have a great potential to differentiate into all cell types, and they have a high ability to… 

Recent Advances in Disease Modeling and Drug Discovery for Diabetes Mellitus Using Induced Pluripotent Stem Cells

Recent advances in the development of techniques for differentiation of iPSCs or DiPSCs into insulin-secreting pancreatic β cells, their applications in drug screening, and their role in complementing and replacing animal testing in clinical use are summarized.

Pluripotent Stem Cell-Derived Pancreatic β Cells: From In Vitro Maturation to Clinical Application

The progress and challenges in the differentiation of PSCs into pancreatic β cells and their therapeutic potentials are discussed and how the use of P SCs and patient-specific PSC's can improve the understanding of the pathophysiology of diabetes and pancreaticβ cell development is described.

Modeling different types of diabetes using human pluripotent stem cells

  • E. Abdelalim
  • Biology, Medicine
    Cellular and Molecular Life Sciences
  • 2020
This review summarizes the current knowledge about different hPSC-based diabetes models and how these models improved the current understanding of the pathophysiology of distinct forms of diabetes, highlights the progress in generating functional β cells in vitro, and discusses the current challenges and future perspectives related to the use of the in vitro hPSCs.

Induced Pluripotent Stem Cells in Disease Modeling and Gene Identification.

The technological perspectives and recent developments in the application of patient-derived iPSC lines for human disease modeling and disease gene identification and developing more precise therapeutics are discussed, including advances in regenerative medicine.

Stem Cell Therapy for Diabetes: Beta Cells versus Pancreatic Progenitors

The co-generation of functionally relevant islet cell subpopulations and structural properties contributing to the glucose responsiveness of beta cells, as well as the available encapsulation technology for these cells are addressed.

Stem Cell-Based Therapies: A New Ray of Hope for Diabetic Patients.

The review attempts to bring into light the clinical studies favoring the transplantation of stem cells in diabetic patients with an objective of improving insulin secretion and improving degeneration of different tissues in response to diabetes.

Engineering Islets From Stem Cells: The Optimal Solution for the Treatment of Diabetes?

In this review, a new approach given high expectations, bioengineered islets from stem cells occupies considerable potential for the future clinical application and addressing the treatment dilemma of diabetes.

Highly Efficient Differentiation of Human Pluripotent Stem Cells into Pancreatic Progenitors Co-expressing PDX1 and NKX6.1.

An in vitro differentiation protocol is optimized to enhance the generation of pancreatic progenitors co-expressing PDX1 and NKX6.1 by modulating cell density, matrix availability, and cellular dissociation.

Genome Editing and Human Pluripotent Stem Cell Technologies for in vitro Monogenic Diabetes Modeling

Human pluripotent stem cell technologies combined with genome editing techniques have been shown to be better alternatives for creating in vitro models that can provide crucial knowledge about disease etiology.

Patients' Induced Pluripotent Stem Cells to Model Drug Induced Adverse Events: A Role in Predicting Thiopurine Induced Pancreatitis?

The probable research applications of exocrine pancreatic cells generated from patient specific iPS cells can provide excellent insights into the molecular mechanism of TIP, which is currently unknown.



Generation of pluripotent stem cells from patients with type 1 diabetes

It is shown that induced pluripotent stem (iPS) cells can be generated from patients with T1D by reprogramming their adult fibroblasts with three transcription factors (OCT4, SOX2, KLF4).

iPS Cells in Type 1 Diabetes Research and Treatment

  • R. Maehr
  • Biology, Medicine
    Clinical pharmacology and therapeutics
  • 2011
There is a need to optimize the differentiation protocols to generate fully glucose‐responsive and mature cells in iPS cells to make possible the generation of patient‐specific disease models that could further the understanding of the root cause of autoimmune diabetes.

Preparation of pancreatic β-cells from human iPS cells with small molecules

The current status of procedures for preparing pancreatic β-cells from human ES/iPS cells, including effective use of small molecules, is summarized, and some of the problems that still need to be overcome are discussed.

Immunological applications of stem cells in type 1 diabetes.

The role of stem cell (SC)-based applications in curing type 1 diabetes is revisited and embryonic SCs also offer exciting prospects because they are able to generate glucose-responsive insulin-producing cells.

Transgene‐Free Disease‐Specific Induced Pluripotent Stem Cells from Patients with Type 1 and Type 2 Diabetes

The Sendai vector system facilitates reliable reprogramming of patient cells into transgene‐free iPSCs, providing a pluripotent platform for personalized diagnostic and therapeutic approaches for diabetes and diabetes‐associated complications.

Differentiation and transplantation of functional pancreatic beta cells generated from induced pluripotent stem cells derived from a type 1 diabetes mouse model.

It is proposed that NOD-iPSCs will provide a useful tool for investigating genetic susceptibility to autoimmune diseases and generating a cellular interaction model of T1D, paving the way for the potential application of patient-derived iPSCs in autologous beta cell transplantation for treating diabetes.

Reversal of hyperglycemia in diabetic mouse models using induced-pluripotent stem (iPS)-derived pancreatic β-like cells

A potential cure for diabetes is described using a cellular therapy to ameliorate symptoms associated with both reduced insulin secretion and insulin sensitivity and an initial proof of principle for potential clinical applications of reprogrammed somatic cells in the treatment of diabetes type 1 or 2 is provided.

A small molecule that directs differentiation of human ESCs into the pancreatic lineage.

A chemical screening platform to investigate human ESC differentiation is described and the generation of a cell population that is a key milepost on the path to making beta cells is demonstrated.

Generation of pancreatic insulin-producing cells from rhesus monkey induced pluripotent stem cells

It is demonstrated for the first time that RM iPSCs can be differentiated into functional insulin- producing cells, which will provide the basis for investigating the efficacy and safety of autologous iPSC-derived insulin-producing cells in a rhesus monkey model for type 1 diabetes therapy.